Oncimmune Holdings PLC Appointment of Non-Executive Director (2886B)

TIDMONC

RNS Number : 2886B

Oncimmune Holdings PLC

09 January 2018

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Appointment of Dr. Annalisa Jenkins as Non-Executive Director

Nottingham, UK - 9 January 2018: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, today announces the appointment of Dr. Annalisa Jenkins, MBBS, FRCP to the Company's Board as Non-Executive Director with immediate effect.

Annalisa has approximately 25 years of experience in building and leading teams that advanced programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Until recently, Annalisa was Chief Executive Officer of Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Dimension Therapeutics was recently acquired by Ultragenyx, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, for approximately $152.3 million in cash.

Prior to this, Dr. Jenkins served as executive vice president, Head of Global Research and Development, at Merck Serono where she also led global medical affairs and quality. Dr. Jenkins also held several roles of increasing responsibility at Bristol Myers-Squibb (BMS), culminating as Senior Vice President and Head of Global Affairs.

Dr. Jenkins has a degree in Medicine from St Bartholomew's Hospital, served as a Medical Officer in the British Navy and was a Specialist Registrar in Cardiovascular Medicine with UK NHS. She currently Chairs the boards of Cell Medica, Vium, Silence Therapeutics and Cocoon Biotech, is a Director on the boards of PhESi, Thrombolytic Science, OncoSec, Ardelyx, iOx Therapeutics and MedCity. In addition, Dr. Jenkins is also a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), an Advisory Board Member at the Centre of Talent Innovation UK and Healthcare Businesswomen's association.

Meinhard Schmidt, Non-Executive Chairman of Oncimmune, commented: "I am delighted to welcome Annalisa to Oncimmune. Her extensive experience across the pharmaceutical and biotechnology industry combined with her expertise in liver diseases and knowledge of companion diagnostics will prove invaluable, both at a Board level and strategically as we continue to commercialise our proprietary EarlyCDT(R) platform technology."

Commenting on her appointment, Annalisa Jenkins said: "Oncimmune's EarlyCDT(R) platform technology has the potential to revolutionise the way cancer is diagnosed by detecting cancer up to four years early. I am excited to be joining the Company at this pivotal time and look forward to working with the team as the Company works to deliver on its portfolio revenue proposition with multiple products, generating revenues in different regions and with different partners."

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

   -      Full name and age: Annalisa Mary Jenkins (née Judd), 52 
   -      Current Directorships: 
   --     Annalisa Jenkins LLC 
   --     Ardelyx, Inc. 
   --     Cocoon Biotech Inc. 
   --     iOX Therapeutics Limited 
   --     MedCity Limited 
   --     OncoSec Medical Incorporated 
   --     The Olivia Rose Fund 
   --     Thrombolytic Science International, LLC 
   --     Vium, Inc. 
   --     YouBelong 
   --     Silence Therapeutics Plc 
   --     Cell Medica Limited 
   --     Pharmaceutical Pipeline Enhancement Strategies, LLC. 
   --     PlaqueTec Limited 
   -      Past Directorships (within the previous 5 years): 
   --     Dimension Therapeutics, Inc. 
   --     Biothera Pharmaceuticals, Inc. 
   --     Prosensa Holding N.V. 
   --     Viventia Bio, Inc. 

Dr. Jenkins does not currently hold any ordinary shares in Oncimmune.

No further information in connection with her appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Giles Balleny, Hugh Kingsmill Moore

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Berenberg (Joint Broker)

Toby Flaux, Charlotte Sutcliffe

[phone]

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT(R)-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT(R)-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT(R)-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT(R) tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOADMGGMMRGGRZZ

(END) Dow Jones Newswires

January 09, 2018 02:00 ET (07:00 GMT)